DNA/MVA HCV疫苗在小鼠和恒河猴中诱导强效广谱细胞与体液免疫
该研究评估了表达H77基因1a型HCV免疫原的DNA初免/MVA加强疫苗的免疫原性。NS免疫原诱导针对多种NS蛋白的CD4和CD8 T细胞反应,S-p7免疫原诱导具有中和活性的E2结合IgG及针对E1/E2的T细胞反应。联合接种可引发针对多数HCV蛋白的T细胞反应,与HCV自愈者的T细胞反应相当。
要点
- DNA初免/MVA加强策略诱导针对多种HCV蛋白的强效广谱CD4和CD8 T细胞反应。
- S-p7免疫原诱导具有自体及异体HCV假病毒中和活性的E2结合IgG。
- 联合接种引发的T细胞反应与HCV自愈者相当,支持HCV疫苗开发。
核心结论
- DNA/MVA初免/加强疫苗接种诱导针对多种HCV蛋白的强效广谱CD4和CD8 T细胞反应及中和抗体反应。
研究设计与样本
- 在小鼠和恒河猴中测试表达H77基因1a型HCV免疫原的DNA初免/MVA加强疫苗,给予2或3剂DNA后1或2剂MVA。
主要发现
- NS免疫原诱导针对多种NS蛋白的CD4和CD8 T细胞反应,CD4主导针对NS3和NS5,CD8主导针对NS3。
- S-p7免疫原诱导E2结合IgG滴度,对自体及异体HCV假病毒颗粒具有中和活性。
- S-p7在恒河猴中诱导针对E1的CD4和CD8 T细胞反应分别为0.08%和0.09%,针对E2分别为0.13%和0.18%。
- 联合接种S-p7和NS疫苗引发针对多数HCV蛋白的T细胞反应,与HCV自愈者的T细胞反应相当。
临床怎么用
- 该疫苗策略支持进一步开发HCV预防性疫苗,需结合临床前免疫原性数据推进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The hepatitis C virus (HCV) is a major cause of liver cirrhosis and cancer in humans, and an effective vaccine is urgently needed. Here, we evaluated the immunogenicity of a DNA prime and modified vaccinia Ankara (MVA) boost vaccine expressing H77 genotype 1a HCV immunogens to induce both T- and B-cell responses. APPROACH AND RESULTS: The non-structural (NS) immunogens expressed NS3, NS4, and NS5. The structural plus p7 immunogen (S-p7) expressed Core, E1, E2, and p7. We tested the immunogenicity of these vaccines in mice and rhesus macaques (RMs) with 2 or 3 doses of DNA followed by 1 or 2 doses of MVA. The NS immunogens induced CD4 and CD8 T-cell responses against multiple NS proteins, with a dominant CD4 T-cell response to NS3 and NS5, and a dominant CD8 T-cell response to NS3. The S-p7 immunogen induced E2-binding IgG titer with neutralizing activity against autologous and heterologous HCV pseudovirus particles. In addition, the S-p7 immunogen induced a CD4 and CD8 T-cell response directed against E1 (0.08% and 0.09%, respectively) and E2 (0.13% and 0.18%, respectively) in RMs. Co-delivery of S-p7 and NS vaccines elicited a T-cell response against the majority of HCV proteins, which was comparable to the T-cell response observed in humans with HCV resolution. CONCLUSIONS: These findings show that the DNA/MVA prime/boost vaccination induces a strong and broad CD4 and CD8 T-cell response to multiple HCV proteins and a neutralizing antibody response. These results aid in the development of vaccines for HCV.
引用
- Rahman SA, Gangadhara S, Gridley J, et al. T- and B-cell-targeting DNA/MVA HCV vaccines induce strong and broad cellular and humoral immunity in mice and rhesus macaques. Hepatology. 2026. PMID: 41790984. doi:10.1097/HEP.0000000000001732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。